Lung Cancer Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation
Top Cited Papers
Open Access
- 23 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 103 (13) , 1058-1068
- https://doi.org/10.1093/jnci/djr173
Abstract
Identification of individuals at high risk for lung cancer should be of value to individuals, patients, clinicians, and researchers. Existing prediction models have only modest capabilities to classify persons at risk accurately. Prospective data from 70 962 control subjects in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) were used in models for the general population (model 1) and for a subcohort of ever-smokers (N = 38 254) (model 2). Both models included age, socioeconomic status (education), body mass index, family history of lung cancer, chronic obstructive pulmonary disease, recent chest x-ray, smoking status (never, former, or current), pack-years smoked, and smoking duration. Model 2 also included smoking quit-time (time in years since ever-smokers permanently quit smoking). External validation was performed with 44 223 PLCO intervention arm participants who completed a supplemental questionnaire and were subsequently followed. Known available risk factors were included in logistic regression models. Bootstrap optimism-corrected estimates of predictive performance were calculated (internal validation). Nonlinear relationships for age, pack-years smoked, smoking duration, and quit-time were modeled using restricted cubic splines. All reported P values are two-sided. During follow-up (median 9.2 years) of the control arm subjects, 1040 lung cancers occurred. During follow-up of the external validation sample (median 3.0 years), 213 lung cancers occurred. For models 1 and 2, bootstrap optimism-corrected receiver operator characteristic area under the curves were 0.857 and 0.805, and calibration slopes (model-predicted probabilities vs observed probabilities) were 0.987 and 0.979, respectively. In the external validation sample, models 1 and 2 had area under the curves of 0.841 and 0.784, respectively. These models had high discrimination in women, men, whites, and nonwhites. The PLCO lung cancer risk models demonstrate high discrimination and calibration.Keywords
This publication has 66 references indexed in Scilit:
- The National Lung Screening Trial: Overview and Study DesignRadiology, 2011
- Evaluating health risk modelsStatistics in Medicine, 2010
- Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 2009
- A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for AdenocarcinomaAmerican Journal of Human Genetics, 2009
- A Prospectively Measured Serum Biomarker for a Tobacco-Specific Carcinogen and Lung Cancer in SmokersCancer Epidemiology, Biomarkers & Prevention, 2009
- Common 5p15.33 and 6p21.33 variants influence lung cancer riskNature Genetics, 2008
- Lung cancer susceptibility locus at 5p15.33Nature Genetics, 2008
- Body Mass Index and Waist Circumference in Relation to Lung Cancer Risk in the Women's Health InitiativeAmerican Journal of Epidemiology, 2008
- Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1Nature Genetics, 2008
- The LLP risk model: an individual risk prediction model for lung cancerBritish Journal of Cancer, 2007